Clinical trials: Stage IV
Carcinoma, Non-Small-Cell Lung, Non-Small Cell Lung Cancer
Study Assessing Safety, Pharmacokinetics and Efficacy of CC-223 With Either Erlotinib or Oral Azacitidine in Advanced Non-Small Cell Lung Cancer
The main purpose of this first study combining an investigational dual mTOR inhibitor, CC-223, with other agents (erlotinib or the investigational agent, oral azacitidine) is to establish a maximum tolerated dose level for each…
- Trial name
- NCT01545947
- Testing
- CC-223, erlotinib, CC-223, oral azacitidine
- Where
- 9 sites in United States, Spain
- Volunteers
- 76 people
- Sponsor
- Celgene
Colorectal Adenocarcinoma
Safety and Efficacy of S-8184 in Second Line Treatment of Stage III or IV Colorectal Adenocarcinoma
Phase IIA, multicenter, dose escalation study evaluating the safety and efficacy of weekly S-8184 paclitaxel injectable emulsion in second line treatment of patients with stage III or IV colorectal adenocarcinoma.
- Trial name
- NCT00034190
- Testing
- S-8184 Paclitaxel Injectable Emulsion
- Where
- Russia
- Volunteers
- 28 people
- Sponsor
- Achieve Life Sciences
Safety/Effacy
Effects of a Nutritional Supplement Combination on Body Weight Management
Title: A Phase IV, Open-label, Single-Center Study on the Effects of a Nutritional Supplement Combination on Body Weight Management over a 90-day period
- Trial name
- NCT01725958
- Testing
- Nutritional supplement and protein shakes
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Pharmanex
HIV Infection
Safety Of VIRACEPT® 625mg Administered To HIV-Infected Women During Pregnancy
This study is an evaluation of the safety of 625 mg formulation when administered to HIV-infected pregnant women from their second trimester through six weeks postpartum.
- Trial name
- NCT00246610
- Testing
- Nelfinavir mesylate, 625 mg
- Where
- 6 sites in United States, Canada
- Volunteers
- 16 people
- Sponsor
- Pfizer
Cerebral Stroke, Thrombosis, Deep Vein
A Study of Adverse Events and Suspected Adverse Drug Reactions in Patients Under Apixaban for Prevention of Stroke and Systemic Embolism With Non-Valvular Atrial Fibrillation and Venous Thromboembolic Events in Patients Who Have Undergone Elective Hip or Knee Replacement Surgery
To characterize and analyze the number, type and incidence of adverse events/suspected adverse drug reactions in patients treated with Apixaban, according to therapeutic indications approved in Mexico.
- Conditions
- Cerebral Stroke, Thrombosis, Deep Vein, Pulmonary Embolism
- Trial name
- NCT03804125
- Sponsor
- Pfizer
Diabetes Mellitus, Type 1
APIDRA Registration Study
To collect effectiveness and safety data during the treatment with Apidra glulisine (HMR1964) by means of subcutaneous injections to patients with Diabetes Mellitus 1st type during 12 weeks-active phase.
- Trial name
- NCT00489190
- Testing
- Insulin Glulisine
- Where
- Kazakhstan
- Volunteers
- 45 people
- Sponsor
- Sanofi
Non-small Cell Lung Cancer
Dose Escalation Of Icotinib In Previously Treated Patients With Routine Dose
To determine whether dose escalation can provide a better survival to patients who failed with icotinib at routine dose.
- Trial name
- NCT01465243
- Testing
- Icotinib
- Where
- China
- Volunteers
- 32 people
- Sponsor
- Betta Pharmaceuticals Co., Ltd.
Type-2 Diabetes Mellitus
Early add-on Vildagliptin in Patients With Type 2 Diabetes Inadequately Controlled by Metformin
The purpose of this study was to observe change of HbA1c over time from baseline to month 12. The ultimate goal of this study was to provide a local reference value to the physicians \& patients in the future when they consider…
- Trial name
- NCT01766778
- Testing
- LAF237 (vildagliptin), Metformin
- Where
- 4 sites in Hong Kong
- Volunteers
- 117 people
- Sponsor
- Novartis Pharmaceuticals
Melanoma, Unresectable (Stage III) Melanoma
RTA 408 Capsules in Patients With Melanoma - REVEAL
Malignant melanoma is a leading cause of death from cutaneous malignancies, accounting for approximately three-fourths of all skin cancer deaths.
- Conditions
- Melanoma, Unresectable (Stage III) Melanoma, Metastatic (Stage IV) Melanoma
- Trial name
- NCT02259231
- Testing
- Omaveloxolone Capsules (2.5 mg/capsule), Ipilimumab (3 mg/kg), Nivolumab (240 mg)
- Where
- 10 sites in United States
- Volunteers
- 41 people
- Sponsor
- Biogen
Healthy
Study of Single Doses of IV Aerucin in Healthy Adults
This study will evaluate the safety profile and pharmacokinetic behavior of a single administration of Aerucin in healthy adults at three different dosages.
- Trial name
- NCT02486770
- Testing
- Aerucin 2.0mg/kg, Aerucin 8.0mg/kg, Aerucin 20.0 mg/kg
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Aridis Pharmaceuticals, Inc.
Hyperkalaemia
Study of SZC and Enhanced Nutrition Advice Compared to SoC in Dialysis Patients With Hyperkalaemia
Prescribing Sodium zirconium cyclosilicate (SZC) with enhanced nutritional advice to participants with hyperkalaemia on haemodialysis will reduce serum K+ (S-K+ ) and enable the consumption of more fruit and vegetables and more…
- Trial name
- GRAZE (NCT04997161)
- Testing
- Sodium Zirconium Cyclosilicate (SZC), Enhanced dietary advice, Standard dietary advice including K+ restriction.
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- AstraZeneca
Neurogenic Overactive Bladder, Urinary Incontinence
Efficacy Study of Pudendal Neuromodulation for the Treatment of Neurogenic Overactive Bladder
The study is designed to demonstrate that treatment with low level stimulation of the bladder muscles reduces symptoms of urinary incontinence in comparison with no stimulation.
- Conditions
- Neurogenic Overactive Bladder, Urinary Incontinence, Detrusor Overactivity
- Trial name
- ACCEPTANCE (NCT01023269)
- Testing
- InterStim Therapy
- Where
- 8 sites in Belgium, France and 4 more
- Volunteers
- 17 people
- Sponsor
- MedtronicNeuro
Hypertension
Efficacy and Safety of S-amlodipine 2,5 mg and 5 mg in Hypertension Patients
s-amlodipine besylate 2,5 mg tablet will be administered to patients have not received any hypertension treatment before or have received any of anti-hypertensive mono-therapy for the first four weeks of treatment.
- Trial name
- NCT03038451
- Testing
- S-NOR (s-amlodipine) 2,5 mg & 5 mg tablet
- Where
- Turkey (Türkiye)
- Volunteers
- 43 people
- Sponsor
- Neutec Ar-Ge San ve Tic A.Ş
Community-acquired Bacterial Pneumonia
A Phase 3b Randomized, Double-blind, Multi-center Study to Compare the Safety and Efficacy of Omadacycline to Moxifloxacin for Treating Adult Subjects With CABP
The primary objective of the study is to show that in Chinese adults with CABP, a course of IV/PO treatment with omadacycline has similar clinical efficacy as the with the comparator antibiotic, IV/PO moxifloxacin.
- Trial name
- public (NCT06162286)
- Testing
- Omadacycline, Moxifloxacin
- Where
- 40 sites in China
- Volunteers
- 100 people
- Sponsor
- Zai Lab (Hong Kong), Ltd.
Non-small Cell Lung Cancer (NSCLC)
A Study of ASP8273 vs. Erlotinib or Gefitinib in First-line Treatment of Patients With Stage IIIB/IV Non-small Cell Lung Cancer Tumors With EGFR Activating Mutations
The purpose of the study was to evaluate the progression free survival (PFS), based on independent radiologic review (IRR), of ASP8273 compared to erlotinib or gefitinib in patients with locally advanced, metastatic or…
- Trial name
- SOLAR (NCT02588261)
- Testing
- naquotinib mesilate, Erlotinib, Gefitinib
- Where
- 167 sites in United States, Australia and 21 more
- Volunteers
- 530 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Venus Leg Ulcer (VLU), VLU
Borate-based Bioactive Glass Fiber Matrix (BBGFM) in the Treatment of Venus Leg Ulcers (VLU)
The goal of this clinical trial is to learn if Borate-based Bioactive Glass Fiber Matrix (BBGFM) can help heal Venous Leg Ulcers (VLU) that have not closed with standard treatment. The main question it aims to answer is: 1.
- Conditions
- Venus Leg Ulcer (VLU), VLU, Venus Leg Ulcer, Venus Ulcer
- Trial name
- NCT07647705
- Testing
- Borate Based Bioactive Glass Fiber Matrix (BBGFM)
- Volunteers
- 110 people
- Sponsor
- ETS Wound Care, LLC
Metastatic Pancreatic Adenocarcinoma
A Study Comparing CO-1.01 With Gemcitabine as First Line Therapy in Patients With Metastatic Pancreatic Adenocarcinoma (LEAP)
The purpose of this study is to determine whether CO-1.01 is safe and effective in the treatment of patients with metastatic pancreatic cancer and low hENT1 expression compared with gemcitabine.
- Trial name
- NCT01124786
- Testing
- CO-1.01, Gemcitabine
- Where
- 95 sites in United States, Argentina and 13 more
- Volunteers
- 367 people
- Sponsor
- Clovis Oncology, Inc.
Metastatic Melanoma
A Phase 3 Pivotal Trial Comparing Allovectin-7® Alone vs Chemotherapy Alone in Patients With Stage 3 or Stage 4 Melanoma
To compare the safety and efficacy of Allovectin-7® versus Dacarbazine (DTIC)or Temozolomide (TMZ) in subjects with recurrent stage 3 or stage 4 melanoma.
- Trial name
- NCT00395070
- Testing
- Allovectin-7®, Dacarbazine (DTIC), Temozolomide (TMZ)
- Where
- 88 sites in United States, Belgium and 12 more
- Volunteers
- 390 people
- Sponsor
- Vical
Carcinoma, Non-Small-Cell Lung, Breast Neoplasms
TR(ACE) Assay Clinical Specimen Study
The TR(ACE) Assay is a quantitative in vitro diagnostic test run on the TR(ACE) Instrument intended for the measurement of high molecular weight human DNA from plasma as an aid to monitoring disease progression or response to…
- Trial name
- NCT02934360
- Testing
- TR(ACE) Assay Testing
- Where
- 16 sites in United States
- Volunteers
- 450 people
- Sponsor
- Biological Dynamics
Cutaneous Melanoma, Relapsed/Refractory, Locally Advanced Unresectable Melanoma (Stage IIIB, IIIC, or IIID)
Study of the Effectiveness and Safety of Acasunlimab Alone and With Pembrolizumab to Treat Advanced Melanoma of the Skin That Has Returned After Treatment With an Approved Checkpoint Inhibitor Therapy (ABBIL1TY MELANOMA-07)
The goal of this clinical trial is to learn about the effectiveness and safety of the bispecific antibody acasunlimab (also known as DuoBody®-PD-L1x4-1BB) when given either alone or together with the cancer drug pembrolizumab in…
- Conditions
- Cutaneous Melanoma, Relapsed/Refractory, Locally Advanced Unresectable Melanoma (Stage IIIB, IIIC, or IIID), Metastatic Cutaneous Melanoma (Stage IV)
- Trial name
- NCT06984328
- Testing
- Acasunlimab, Pembrolizumab
- Where
- 2 sites in United States, Puerto Rico
- Volunteers
- 1 people
- Sponsor
- Genmab
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.